Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand
MWN-AI** Summary
Optimi Health Corp. recently marked a significant milestone in the realm of psychedelic research by announcing the successful dosing of the first participants in a groundbreaking psilocybin study in New Zealand. This clinical trial, supported by T? Wairua and the M?tai Medical Research Institute, aims to tackle methamphetamine addiction through an innovative approach that merges traditional M?ori healing practices with contemporary clinical methods.
The use of Optimi's natural psilocybin extract in this study at Rangiwaho Marae represents a historic union of indigenous knowledge (m?tauranga M?ori) and psychedelic therapy. Participants have undergone preparatory sessions for psilocybin-assisted therapy, conducted in a culturally immersive setting which reveres the importance of community and cultural protocols (tikanga).
Dane Stevens, CEO of Optimi, emphasized the immense value of integrating indigenous frameworks with modern science to confront pressing mental health issues. He expressed pride in the use of their psilocybin extract in such a culturally significant study.
Lead investigator, Dr. Patrick McHugh, noted that this trial enriches the clinical framework by honoring the mana (spiritual power) and well-being of the participants and their communities while exploring the therapeutic potential of psilocybin. The T? Wairua initiative, working in tandem with partners like Rua Bioscience and the Institute of Environmental Science and Research, embodies collaborative efforts in advancing psychedelic medicine responsibly.
As the study progresses, findings will not only enhance understanding of psilocybin-assisted therapies but also pave the way for future research endeavors in psychedelic medicine, with Optimi poised to support further innovative projects in the field.
MWN-AI** Analysis
Optimi Health Corp.’s recent announcement regarding the dosing of the first participants in a natural psilocybin study in New Zealand marks a significant milestone in the expanding field of psychedelic medicine. This innovative approach combines indigenous M?ori healing traditions with modern clinical research, focusing on addressing methamphetamine addiction. The culturally significant framework of the T? Wairua initiative not only enhances the therapeutic potential of psilocybin but also underscores the company's commitment to responsible and inclusive research practices.
Investors should monitor Optimi Health’s progress closely, as positive outcomes from this study could lead to increased credibility and market validation for the company’s psilocybin extract. The integration of traditional healing practices into clinical settings could also position Optimi as a leader in the emerging market for psychedelics designed for mental health and addiction treatment.
With Health Canada licensing and GMP compliance, Optimi is strategically poised to capitalize on a growing interest in psychedelic-assisted therapies, especially if the New Zealand study yields promising results. The emphasis on community well-being and safety not only enhances the ethical standing of the research but also appeals to a socially conscious investor base.
Entrants to the psychedelic space often face regulatory challenges, but Optimi’s commitment to rigorous compliance may provide a competitive advantage. As the company continues to produce high-quality, natural psilocybin, the potential for expanded research partnerships and future trials could contribute to sustainable growth.
Investors should remain aware of the inherent risks listed in forward-looking statements, especially those associated with clinical outcomes and market acceptance. However, if the New Zealand study proves successful, Optimi could experience significant market traction, making it a noteworthy consideration for those looking to invest in the psychedelic realm.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
The Company's natural psilocybin extract powers a culturally transformative study to address methamphetamine addiction through indigenous frameworks.
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in natural psilocybin and MDMA, is proud to announce that its natural psilocybin extract has been successfully exported to New Zealand. The shipment has enabled the dosing of the first participants using Optimi's natural psilocybin extract in a groundbreaking clinical trial supported by T? Wairua, and the M?tai Medical Research Institute, based in Gisborne, New Zealand.
The study is the first of its kind, combining indigenous M?ori knowledge systems (m?tauranga M?ori) with cutting-edge clinical methodologies to address methamphetamine addiction. The inaugural cohort of participants has completed preparatory sessions and received psilocybin-assisted therapy in a culturally grounded, marae-based setting using Optimi's natural psilocybin extract.
Key Highlights
- First Participants Dosed: Optimi's natural psilocybin extract was administered to participants at Rangiwaho Marae, marking a historic step in combining traditional healing frameworks with modern therapeutic approaches.
- Innovative Collaboration: The T? Wairua initiative unites indigenous leaders, health researchers, and industry partners, including Rua Bioscience (NZX:RUA) and the Institute of Environmental Science and Research (ESR), to explore the therapeutic potential of taonga (mushroom) varieties.
- Cultural Integration: The trial emphasizes tikanga (cultural protocols) and collective reflection to ensure the safety, feasibility, and long-term well-being of participants and their communities.
Supporting Indigenous Leadership in Psychedelic Therapies
"This is an incredible moment for Optimi and for the field of psychedelic medicine," said Dane Stevens, CEO of Optimi. "We are deeply honored to see our natural psilocybin extract being utilized in such a meaningful and culturally significant study. The T? Wairua initiative is a testament to how modern science and indigenous knowledge can come together to address some of the world's most pressing mental health challenges. We look forward to continuing our support for groundbreaking programs like this, which have the potential to transform lives and inspire global change."
Dr. Patrick McHugh, lead investigator for the study and researcher at M?tai Medical Research Institute, stated, "The successful dosing of our first participants marks an important milestone in our work to address methamphetamine addiction through culturally grounded interventions. By integrating m?tauranga M?ori and tikanga into the clinical framework, we're not only exploring the therapeutic potential of psilocybin but also honoring the mana and well-being of the participants and their communities."
Building a Framework for Global Psychedelic Innovation
The study, supported by Rua Bioscience and other New Zealand-based organizations, is a testament to the global collaboration required to advance psychedelic medicine responsibly. Optimi's involvement underscores the Company's mission to make high-quality, natural psilocybin accessible to researchers and patients worldwide.
Learnings from this clinical trial will inform future trial phases and contribute to the broader understanding of psilocybin-assisted therapies.
Optimi invites research groups interested in utilizing its GMP-certified psilocybin to contact sales@optimihealth.ca for access to the investigator's brochure and pricing details.
About Optimi Health Corp.
Optimi Health Corp. is a Health Canada-licensed, GMP-compliant manufacturer and supplier of natural psilocybin and MDMA. Dedicated to producing high-quality psychedelic products, the Company aims to support the global advancement of mental health therapies through rigorous compliance, innovation, and collaboration.
On Behalf of the Board
JJ Wilson, Chair of the Board
For more information, please contact:
Optimi Health Corp.
Telephone: (778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca
Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"), including statements pertaining to the study, the results of such study, the benefits of using psilocybin and the potential for follow on studies. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's long form prospectus dated February 12, 2021, a copy of which is available on SEDAR+ at www.sedarplus.ca. Except as expressly required by applicable law, Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236949
FAQ**
How does Optimi Health OPTHF ensure the quality and safety of its natural psilocybin extract in the groundbreaking clinical trial addressing methamphetamine addiction?
What specific metrics will be used to evaluate the success of the collaboration between Optimi Health OPTHF, T? Wairua, and M?tai Medical Research Institute during this study?
In what ways does the integration of m?turanga M?ori enhance the therapeutic potential of psilocybin-assisted therapy in this clinical trial for Optimi Health OPTHF?
What are the company's plans for further research or trials following the outcomes of this initial study on psilocybin’s effectiveness in treating methamphetamine addiction at Optimi Health OPTHF?
**MWN-AI FAQ is based on asking OpenAI questions about Optimi Health Corp. (CNQC: OPTI:CC).
NASDAQ: OPTI:CC
OPTI:CC Trading
-3.51% G/L:
$0.275 Last:
21,514 Volume:
$0.285 Open:
